Stockscreener 앱 받기
16.33
10.86%
1.60
시간 외 거래:
16.59
0.26
+1.59%
전일 마감가:
$14.73
열려 있는:
$15.06
하루 거래량:
2.50M
Relative Volume:
2.04
시가총액:
$937.93M
수익:
-
순이익/손실:
$-52.79M
주가수익비율:
-20.97
EPS:
-0.7789
순현금흐름:
$-53.49M
1주 성능:
+16.64%
1개월 성능:
+23.34%
6개월 성능:
+188.01%
1년 성능:
+849.42%
1일 변동 폭
$14.24
$17.00
1주일 범위
$13.20
$17.00
52주 변동 폭
$1.54
$17.00
Climb Bio Inc Stock (CLYM) Company Profile
명칭
Climb Bio Inc
전화
1-866-857-2596
주소
20 WILLIAM STREET, WELLESLEY HILLS
Compare CLYM vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CLYM
Climb Bio Inc
|
16.33 | 826.51M | 0 | -52.79M | -53.49M | -0.7789 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Climb Bio Inc Stock (CLYM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-15 | 개시 | Mizuho | Outperform |
| 2026-03-24 | 개시 | B. Riley Securities | Buy |
| 2026-03-18 | 개시 | Truist | Buy |
| 2026-03-11 | 개시 | Raymond James | Strong Buy |
| 2026-03-05 | 개시 | Wedbush | Outperform |
| 2026-02-13 | 개시 | Piper Sandler | Overweight |
| 2025-10-16 | 개시 | William Blair | Outperform |
| 2025-10-13 | 개시 | H.C. Wainwright | Buy |
| 2025-08-15 | 개시 | Robert W. Baird | Outperform |
| 2025-06-06 | 개시 | Oppenheimer | Outperform |
| 2025-05-22 | 개시 | BTIG Research | Buy |
| 2024-12-02 | 개시 | Leerink Partners | Outperform |
모두보기
Climb Bio Inc 주식(CLYM)의 최신 뉴스
Dimensional Fund Advisors LP Buys Shares of 104,437 Climb Bio, Inc. $CLYM - marketbeat.com
Climb Bio, Inc. (CLYM): MPM BioImpact LLC reports 0% ownership in amendment - Stock Titan
Climb Bio Collaborator Beijing Mabworks Begins Phase 2 Trial Dosing for IgA Nephropathy in China - Kalkine Media
Climb Bio (NASDAQ:CLYM) Shares Up 8.2%Still a Buy? - marketbeat.com
symbol__ Stock Quote Price and Forecast - CNN
Climb Bio Advances Phase 2 Renal Disease Trial - TipRanks
Climb Bio and Mabworks begin dosing in Phase 2 trial for kidney disease in China - Investing.com Canada
Form 8K Climb Bio Inc For: 14 August By Investing.com - Investing.com Canada
Climb Bio (NASDAQ:CLYM) Hits New 12-Month HighWhat's Next? - marketbeat.com
Renaissance Technologies LLC Lowers Holdings in Climb Bio, Inc. $CLYM - marketbeat.com
We Think Climb Bio (NASDAQ:CLYM) Can Afford To Drive Business Growth - moomoo.com
Climb Bio (NASDAQ:CLYM) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
RBC Capital Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Oppenheimer Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Climb Bio (NASDAQ:CLYM) Hits New 12-Month High Following Strong Earnings - marketbeat.com
Climb Bio (NASDAQ:CLYM) Price Target Raised to $25.00 - marketbeat.com
BTIG Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $20 - Moomoo
CLIMB BIO INC : TRUIST SECURITIES RAISES TARGET PRICE TO $25 FROM $17 - Bitget
Climb Bio, Inc. Stock 12‑Month Price Target Raised to $21.93, Implies 76% Upside - TradingView
Climb Bio Advances Budoprutug Lupus Trial, Keeping Investors Tuned to Early-Stage Data - TipRanks
Climb Bio Releases Q2 2026 Financial Results - AlphaStreet
Climb Bio Reports Q2 2026 Financial Results and Pipeline Updates in Nasdaq 10-Q Filing - Kalkine Media
Climb Bio, Inc. Q2 2026: Net loss $(13.5M), EPS $(0.18) — 10-Q Summary - TradingView
CLYM: $239.2M cash, $13.5M Q2 net loss, and $103.4M raised to fund clinical pipeline into 2028 - TradingView
Climb Bio (Nasdaq: CLYM) raises $103M, extends cash runway into 2028 - Stock Titan
Climb Bio reports Q2 2026: $239.2M cash, net loss $13.5M; advances CLYM116 and budoprutug programs - TradingView
CLYM: Advanced clinical pipeline and secured $239M cash, extending runway into 2028 - tradingview.com
Climb Bio (Nasdaq: CLYM) details pipeline progress and funding into 2028 - Stock Titan
Climb Bio Q2 net loss widens on pipeline advancement - TradingView
Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Climb Bio (CLYM) Projected to Post Earnings on Tuesday - MarketBeat
Climb Bio (NASDAQ:CLYM) Rating Increased to Moderate Buy at Royal Bank Of Canada - MarketBeat
CLIMB BIO INC : RBC INITIATES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $23 - Bitget
RBC Capital Initiates Climb Bio at Outperform With $23 Price Target - marketscreener.com
RBC Capital Initiates Climb Bio(CLYM.US) With Buy Rating, Announces Target Price $23 - moomoo.com
Climb Bio, Inc. (NASDAQ:CLYM) Given Consensus Rating of "Buy" by Brokerages - marketbeat.com
Climb Bio’s Budoprutug Trial Completion Sets Stage for Next Investor Catalyst - TipRanks
Climb Bio Inc. (CLYM) Q1 2026 Earnings: Narrower-than-Expected Loss Lifts SharesBanking Earnings Report - dars.gov.et
ADAR1 Capital Management LLC Sells 834,813 Shares of Climb Bio, Inc. $CLYM - marketbeat.com
Climb Bio Inc (CLYM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Climb Bio Builds Momentum With Late-2026 Data Readouts; Wedbush Sets $20 Target - RTTNews
CLYM Maintained by Wedbush -- Price Target Raised to $20.00 - GuruFocus
Climb Bio Inc (CLYM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Wedbush Raises Price Target on Climb Bio to $20 From $17, Keeps Outperform Rating - Moomoo
Climb Bio Inc (CLYM) Cash Flow - TradingKey
Climb Bio Inc (CLYM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Climb Bio Inc (CLYM) Institutional Confidence - TradingKey
Wedbush Forecasts Strong Price Appreciation for Climb Bio (NASDAQ:CLYM) Stock - marketbeat.com
CLYM|Climb Bio Inc|Price:12.780|Chg%:-0.060 - TradingKey
Climb Bio Inc (CLYM) Valuation: PE, PB & Fair Value Analysis - TradingKey
Climb Bio Inc. (CLYM) Edges Higher as Stock Tests Key ResistanceStock Analysis - dars.gov.et
Climb Bio Inc (CLYM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.07%
자본화:
|
볼륨(24시간):